AIM VACCINE

Le Meridien Vaccine is a large-scale private vaccine group with a full industry chain in China. Its business covers the entire industry value chain from R&D to manufacturing to commercialization. It obtained batches of about 60 million doses in 2020, achieving sales of vaccine products to 31 provinces, autonomous regions and municipalities directly under the Central Government of China. Le Meridien has five vaccine companies that have proven human vaccine platform technology, which greatly guarantees the speed and flexibility of the company's development. Currently, the company has 8 commercial vaccines for 6 disease fields and 23 innovative vaccines under development for 13 disease fields. The products in production and development cover all of the world's top ten vaccine products (based on global sales in 2020).

Through ten years of development, the company has developed an inclusive and pioneering business model and corporate culture, through which it has been able to continuously expand and optimize its existing business. Currently, four licensed vaccine manufacturers are wholly owned, namely Le Meridien, Emmy Conhuai, Emmy Weixin, and Rongan Biotech. It owns 3 research institutes, of which the R&D center, Le Meridien Explorer, which was built in 2018, focuses on providing technical support for early and cutting-edge research by R&D departments in various factories. Le Meridien acquired Zhuhai Lifanda Biotechnology Co., Ltd. in 2021. The company is one of only 3 domestic companies to obtain approval for clinical trials of the mRNA COVID-19 vaccine, and has an independent mRNA production and drug delivery technology platform.

Le Meridien Vaccine Group has always adhered to the mission of “making vaccines of conscience and living a healthy world” and strictly controls the quality of vaccines. The company is equipped with a professional and dedicated sales team composed of more than 100 members with an average of more than 10 years of experience in drug or vaccine sales. The core business leadership team has an average of 12 years of vaccine commercialization experience for multinational pharmaceutical companies, and has excellent results in marketing major international vaccines (including the world's first HPV, IPV, and dTAP-IPV-Hib). The products currently on sale mainly include recombinant hepatitis B vaccine (Hanson's yeast), freeze-dried human rabies vaccine (Vero cells), hepatitis A inactivated vaccine (human diploid cells), live attenuated mumps vaccine, bivalent renal syndrome hemorrhagic fever inactivated vaccine (Vero cells), and ACYW135 group meningococcal polysaccharide vaccine (MPSV4).